Literature DB >> 30177549

SuPAR, an emerging biomarker in kidney and inflammatory diseases.

Lamiaa Hamie1, Georges Daoud1, Georges Nemer2, Tarek Nammour3, Alissar El Chediak3, Imad W Uthman3, Abdul Ghani Kibbi4, Assaad Eid1, Mazen Kurban5,4.   

Abstract

Soluble urokinase plasminogen activator receptor (suPAR) is a circulating form of a physiological and pathophysiological important cell surface receptor, implicated in inflammation. Recent studies showed that suPAR is a promising biomarker, useful for diagnosis, assessment and prognosis of several diseases. This review summarises the majority of preliminary studies and analyses the significance and the clinical application of suPAR in various clinical conditions. SuPAR seems to have a significant value in the diagnosis as well as prognosis of many diseases; nonetheless, it merits large-scale studies to set cut-off values that help physicians in following up their patients and accordingly tailor their treatment plans. © Author(s) (or their employer(s)) 2018. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  biomarker; diagnosis; inflammation; prognosis; screen; soluble urokinase plasminogen activator receptor

Mesh：

Substances：

Year:  2018        PMID： 30177549     DOI： 10.1136/postgradmedj-2018-135839

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN： 0032-5473            Impact factor:   2.401


  17 in total

1.  Novel Pure αVβ3 Integrin Antagonists That Do Not Induce Receptor Extension, Prime the Receptor, or Enhance Angiogenesis at Low Concentrations.

Authors:  Jihong Li; Yoshiyuki Fukase; Yi Shang; Wei Zou; José M Muñoz-Félix; Lorena Buitrago; Johannes van Agthoven; Yixiao Zhang; Ryoma Hara; Yuta Tanaka; Rei Okamoto; Takeshi Yasui; Takashi Nakahata; Toshihiro Imaeda; Kazuyoshi Aso; Yuchen Zhou; Charles Locuson; Dragana Nesic; Mark Duggan; Junichi Takagi; Roger D Vaughan; Thomas Walz; Kairbaan Hodivala-Dilke; Steven L Teitelbaum; M Amin Arnaout; Marta Filizola; Michael A Foley; Barry S Coller
Journal:  ACS Pharmacol Transl Sci       Date:  2019-08-02

Review 2.  Soluble Urokinase Receptor and Liver Disease.

Authors:  Changli Wei; Ke Zhu; Jochen Reiser
Journal:  Clin Liver Dis (Hoboken)       Date:  2019-12-20

3.  Serum soluble urokinase plasminogen activator receptor in adolescents: interaction of chronic pain and obesity.

Authors:  Hershel Raff; Jonathan M Phillips; Pippa M Simpson; Steven J Weisman; Keri R Hainsworth
Journal:  Pain Rep       Date:  2020-07-22

4.  Effect of Sickle Cell Trait and APOL1 Genotype on the Association of Soluble uPAR with Kidney Function Measures in Black Americans.

Authors:  Alexander P Reiner; Laura M Raffield; Nora Franceschini; Paul L Auer; Ethan M Lange; Deborah A Nickerson; Neil A Zakai; Adolfo Correa; Nels Olson
Journal:  Clin J Am Soc Nephrol       Date:  2020-12-02       Impact factor: 8.237

5.  Expression of the Novel Cardiac Biomarkers sST2, GDF-15, suPAR, and H-FABP in HFpEF Patients Compared to ICM, DCM, and Controls.

Authors:  Peter Jirak; Rudin Pistulli; Michael Lichtenauer; Bernhard Wernly; Vera Paar; Lukas J Motloch; Richard Rezar; Christian Jung; Uta C Hoppe; P Christian Schulze; Daniel Kretzschmar; Rüdiger C Braun-Dullaeus; Tarek Bekfani
Journal:  J Clin Med       Date:  2020-04-15       Impact factor: 4.241

6.  Neutrophils are a main source of circulating suPAR predicting outcome in critical illness.

Authors:  Hendrik Gussen; Philipp Hohlstein; Matthias Bartneck; Klaudia Theresa Warzecha; Lukas Buendgens; Tom Luedde; Christian Trautwein; Alexander Koch; Frank Tacke
Journal:  J Intensive Care       Date:  2019-04-27

7.  Serum soluble urokinase type plasminogen activated receptor and focal segmental glomerulosclerosis: a systematic review and meta-analysis.

Authors:  Tiankui Shuai; Yan Pei Jing; Qiangru Huang; Huaiyu Xiong; Jingjing Liu; Lei Zhu; Kehu Yang; Liu Jian
Journal:  BMJ Open       Date:  2019-10-07       Impact factor: 2.692

8.  Soluble urokinase plasminogen activator receptor associates with higher risk, advanced disease severity as well as inflammation, and might serve as a prognostic biomarker of severe acute pancreatitis.

Authors:  Qi Zhang; Le Li; Hongze Chen; Guangquan Zhang; Siqiang Zhu; Rui Kong; Hua Chen; Gang Wang; Bei Sun
Journal:  J Clin Lab Anal       Date:  2019-11-27       Impact factor: 2.352

9.  Sex Differences in Circulating Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels and Adverse Outcomes in Coronary Artery Disease.

Authors:  Anurag Mehta; Shivang R Desai; Yi-An Ko; Chang Liu; Devinder S Dhindsa; Aditi Nayak; Ananya Hooda; Mohamed A Martini; Kiran Ejaz; Laurence S Sperling; Jochen Reiser; Salim S Hayek; Arshed A Quyyumi
Journal:  J Am Heart Assoc       Date:  2020-02-22       Impact factor: 5.501

10.  Association of soluble urokinase plasminogen activator receptor levels with fibrotic and vascular manifestations in systemic sclerosis.

Authors:  Sheraz Butt; Jørgen L Jeppesen; Line Vinderslev Iversen; Mogens Fenger; Jesper Eugen-Olsen; Charlotte Andersson; Søren Jacobsen
Journal:  PLoS One       Date:  2021-02-22       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.